The iconic Ratio Eight coffee maker just got a major upgrade
Ratio's iconic Series 8 coffee maker just got a major upgrade.
With its timeless combination of Chemex and pour-over, the OG has ben around since 2014, and while it's still a classic choice, Ratio has announced the new Series 2: "a new chapter for a modern classic".
Shipping from September, the Series 2 is sure to be a hit. It takes the much-loved features of its predecessor to create something standout.
Price-wise, it's $799, though at time of writing it was discounted to $639 for pre-orders. Plus, an extra $100 for a thermal carafe.
The Ratio Eight Series 2 is an upgrade on the original, boasting dual recipe brew programs, a stainless steel and handblown glass pairing with a solid walnut trim, a flat bottom filter basket and added heat shield. This stylish update takes from the previous Eight Series and makes it, well, better. If you'd like the thermal carafe, it's an additional $100 on top of this price.
The Ratio Eight coffee maker is a unique mix of pour-over and Chemex brewing. A complicated process if you're tackling it alone, but with Ratio's intricately designed smart technology, it's a whole lot simpler.
And while the technique it emulates is complex, the design of this coffee maker is simplicity at its finest. A mixture of premium materials, it's eye-catching and chic – blending matte and glass with a wood trim.
With all this in mind, it's a huge hit with coffee pros for both what it offers to simplifying the pour-over process and the beauty of its design.
Get instant access to breaking news, the hottest reviews, great deals and helpful tips.
As the original Ratio Eight has been on the market for a decade now, there's a lot that's been learnt, and the Series 2 incorporates these tweaks into a new coffee maker that is sure to impress.
So, with the Ratio Eight Series 2 model, the team has made some awesome upgrades. These include a flat brewer basket for a more even extraction, a heat shield for hotter coffee (though you can add the thermal carafe for $100, too), a better glass carafe for easier pouring, and the inclusion of a half batch and full batch button activated by long touch.
These days, a coffee maker will typically lean towards a more modern design, like the Fellow Aiden for example. It's incredibly sleek, but the Ratio Eight series is focused on a different design – creating a midcentury look.
With a combination of glass, matte premium materials and a sophisticated wood trim, it's a stylish and nostalgic option when compared to the best coffee makers currently on the market.
Crafted in Portland, a city that you'll often hear married with the words "hip" and "trendy", it should come as no surprise that the Ratio Eight is made in Oregon.
Plus, it's backed by a 5-year warranty, meaning Ratio is pretty confident you'll be getting wonderfully brewed pour-over coffee for years to come with little hassle.
But while it won't be available for a couple of months yet, we'll be first in line to get our hands on this impressive Series 2 upgrade, and we'll follow it up with a review of our own.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
4 hours ago
- Business Insider
Here are 10 stocks Goldman Sachs expects to be winners after a wild first half for the market
Goldman Sachs just updated one of its stock baskets with its picks for the highest risk-adjusted returns. The basket has outperformed the S&P 500 so far this year, gaining 3% year-to-date. The S&P 500's overall risk-adjusted return has been lower than usual so far this year, strategists said. It's been a volatile year for stock traders, but there are a handful of new winners in the S&P 500 that could be poised for big gains over the next 12 months, according to Goldman Sachs. In a note to clients on Friday, the bank said it updated its Sharpe Ratio basket, a list of 50 stocks with the highest expected risk-adjusted returns. So far, the basket has gained 3% year-to-date, edging past the S&P 500's 1.7% gain. The S&P 500's overall risk-adjusted return has been "lower than usual" so far in 2025, the strategists said, pointing to increased volatility and lower-than-average returns stemming from fears around tariffs. The bank rebalanced its portfolio by choosing stocks with a high prospective Sharpe Ratio, a gauge for risk-adjusted returns calculated by dividing a percentage return to a stock's consensus 12-month price target by its six-month option-implied volatility. "Currently, the median S&P 500 stock is expected to post an 11% return to its 12-month consensus price target with a 6-month implied volatility of 28, yielding a prospective risk-adjusted return of 0.4," the bank wrote. Here are the top 10 newest additions to Goldman's Sharpe basket. 1. Moderna Ticker: MRNA Return to consensus price target: 88% Expected return over implied volatility: 1.3 2. Viatris ELSA BIYICK/Hans Lucas/AFP via Getty Images Ticker: VTRS Return to consensus price target: 61% Expected return over implied volatility: 1.5 3. Enphase Energy Ticker: ENPH Return from consensus price target: 45% 4. PG&E Corp Ticker: PCG Return to consensus price target: 45% Expected return over implied volatility: 1.1 5. Thermo Fisher Scientific Return to consensus price target: 42% Expected return over implied volatility: 1.2 6. Fiserv Ticker: FI Return to consensus price target: 37% Expected return over implied volatility: 1.2 7. Cooper Companies EyeEmTicker: COO Return to consensus price target: 37% Expected return over implied volatility: 1.2 8. Salesforce Ticker: CRM Return to consensus price target: 37% Expected return over implied volatility: 1.1 9. Lennar Corp Ticker: LEN Return to consensus price target: 34% Expected return over implied volatility: 0.9 10. EPAM Systems Return to consensus price target: 33%
Yahoo
13-06-2025
- Yahoo
Ratio Therapeutics Partners with Macrocyclics for Exclusive Manufacturing and Distribution of its Radiopharmaceutical Chelator Platform
BOSTON, June 13, 2025 /PRNewswire/ -- Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, announced today that it entered into an agreement granting Macrocyclics Inc. (Macrocyclics) exclusive manufacturing and distribution rights to Ratio's proprietary chelator Macropa™ enabling broad access worldwide. Macropa is a proprietary, best-in-class, bifunctional chelator for Actinium-225 (Ac-225), known for its strong alpha-particle emissions and its use in targeted alpha therapy (TAT) for the treatment of cancer. Macropa can be tethered to small molecules, peptides, and large polypeptides such as proteins and antibodies to enable the development of targeted radiopharmaceuticals for alpha radiotherapy. By rapidly and quantitatively complexing Ac-225 at room temperature, Macropa's unique selectivity and stability for Ac-225 enables simple "one-pot" manufacturing and improves in vivo stability of the resulting compound. "Over the past year, we have been focused on building global scientific awareness and encouraging adoption of our chelator platform across the therapeutic radiopharmaceutical community," said Bill Cupelo, Chief Business Officer of Ratio. "We are proud to see our efforts realized through an expanding global ecosystem of collaborators who can now leverage Macropa to accelerate the development and adoption of radiopharmaceuticals worldwide. By enabling broader access to our platform, we are fostering a global community aligned in the mission to improve patient outcomes through targeted cancer therapies and diagnostics." Incorporated in 1995, Macrocyclics is a CDMO specialized in chelating agents for radiopharmaceuticals and nuclear medicine. The company maintains a broad catalog of bifunctional chelating agents that are used in R&D and clinical programs across the globe. Under the terms of the agreement, researchers from academia and industry may purchase Macropa directly from Macrocyclics, enabling rapid access in many countries including Japan, Canada, Australia and majority of Europe. "Ratio's Macropa is a superior chelator for Ac-225," said Paul Jurek, Ph.D., CEO of Macrocyclics. "The ability to label quickly at room temperature provides a critical advantage, especially when working with proteins or vectors that degrade when heated. We are excited to be the exclusive manufacturer of Macropa and plan to add multiple derivatives to our catalog and provide it under GMP conditions for innovators engaged in clinical research." Macrocyclics is an exhibitor at the 2025 SNMMI Annual Meeting, located in New Orleans, LA from June 21 to June 24. Ratio will also have representatives in attendance and will host a networking event for current and potential Macropa users. About Macrocyclics Macrocyclics, Inc., founded in 1995 with headquarters in Plano, Texas, is a CDMO specializing in chelating agents for radiopharmaceuticals and nuclear medicine. A subsidiary of Orano Med, the company stocks a catalog of products dedicated to chelation technology including bifunctional chelators, magnetic resonance agents, and reactive intermediates. The company supports rapid advancements in the field through its GMP compliant quality system, custom small molecule synthesis capabilities, and expertise in analytical development and characterization. For more information about the company, please visit: About Ratio Therapeutics Ratio Therapeutics Inc. is a clinical-stage pharmaceutical company with the mission to accelerate the development of next-generation precision radiopharmaceuticals for solid tumors and transform oncology treatment paradigms. With headquarters and laboratories in Boston, the company currently employs a growing team of multidisciplinary experts with backgrounds in radiopharmaceutical discovery and development. Ratio's proprietary R&D platforms, Trillium™ and Macropa™, enable the development of fit-for-purpose radiopharmaceuticals for therapy and imaging that possess pharmacokinetic modulation, thereby improving drug availability, tumor delivery, and tumor loading. The company is also currently advancing the development of its first FAP-targeted radiotherapeutic with plans to enter clinical trials this year. Please visit for more information and follow us on Twitter (X) and LinkedIn. For information regarding ordering Macropa, please contact Macrocyclics at info@ View original content to download multimedia: SOURCE Ratio Therapeutics Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
USA Today
12-06-2025
- USA Today
Texas A&M transfer WR signs NIL deal with trading card company
Texas A&M transfer WR signs NIL deal with trading card company Texas A&M's 2025 wide receiver rotation is completely revamped after the additions of KC Concepcion (NC State), Jonah Wilson (Houston), and Mario Craver (Mississippi State) this offseason, while the return of Terry Bussey, Ashton Bethel-Roman and Izaiah Williams has given starting quarterback Marcel Reed an elite corps that should take the Aggie passing game to the next level. With elite talent comes NIL earnings, and after the NCAA vs. House bill was passed, Universities will now directly pay their athletes with a $20.5 million cap per institution. At the same time, players will continue to be able to sign NIL deals with various organizations. This week, it was revealed that KC Concepcion signed a $2.5 million deal with The Famile. In contrast, Jaxson Callaway of AggiesToday revealed on Wednesday that Marion Craver has reportedly signed his NIL deal with Topps Trading Cards. According to Callaway, Craver will work with a variety of trading cards ranging from Autograph, Relic, Chrome, and Specialty Sets. As Callaway notes in the article, Craver's ascending profile and star potential after his freshman season with the Bulldogs are the primary reasons Topps is so excited about his representation moving forward. "Mario Craver is as an emerging figure in the trading card market, leveraging his collegiate status to contribute to Topps' diverse portfolio. The inclusion of autographs and jerseys taps into the growing demand for authenticated memorabilia, especially as Topps expands with 2025 releases like Series 2 and Chrome. Collectors can anticipate Craver's cards in hobby boxes or as standalone rarities, available through Topps' official site or retailers like Target, with potential value increases if his career progresses." Craver enters the 2025 season as the No. 2 or 3 option, depending on the results of fall practices, providing Marcel Reed with a legitimate deep threat who can take the top of most secondaries. His quickness in route will create immediate separation in the short passing game. Contact/Follow us @AggiesWire on X (formerly Twitter) and like our page on Facebook to follow ongoing coverage of Texas A&M news, notes and opinions. Follow Cameron on X: @CameronOhnysty.
